-
March 18, 2021
Covid-19 Is Big Business. But Who’s Making a Killing?
You’d think that in a global pandemic, the fate of billions of people around the planet would be the first priority of our governments rather catering to the pharmaceutical industry. But you’d be wrong.
Gregg Gonsalves
-
February 8, 2021
Want to Reverse Inequality? Change Intellectual Property Rules.
Changes in IP have done far more than tax cuts to increase inequality—and US protection of IP could lead to a cold war with China.
Dean Baker
-
January 27, 2021
We Already Paid for These Vaccines Once
So why do we talk about Pfizer or Moderna, when these should be the people’s vaccines?
Reshma Ramachandran and Zoey Thill
-
July 28, 2020
The US Chamber of Commerce Says Trump Is Bad for Business
The administration’s in hot water with corporate America for draconian work visa policies.
Sasha Abramsky
-
November 22, 2019
How Can Big Pharma Make Amends for the Opioid Epidemic?
It’s unlikely pharmaceutical executives will face a full reckoning in court, but transformative justice could give victims the relief they deserve.
Mattea Kramer
-
GET UNLIMITED DIGITAL ACCESS FOR LESS THAN $3 A MONTH!
-
April 1, 2019
Is the FDA Misleading Congress About the Safety of Imported Medicines?
Prescription drugs can cost 80 percent less in Canada, Australia, and the UK—why isn’t the FDA supporting safe importation?
Gabriel Levitt
-
January 31, 2019
Forget the Wall—the Opioid Crisis Is Trump’s Real National Emergency
Opioid overdoses claimed nearly 50,000 American lives in 2017 alone, more than 9/11 and the wars in Iraq and Afghanistan combined.
Rajan Menon
-
December 21, 2018
The Battle Over NAFTA 2.0 Has Just Begun
Progressives must fight strategically to improve it—if they don’t, the consequences could be devastating.
Lori Wallach
-
October 2, 2018
Pharmaceutical Giants Have Avoided Paying About $2.3 Billion in Taxes in the US Alone
Could that money be used to fund a more humane health-care system?
Michelle Chen
-
October 1, 2018
Can the US Provide a Public Option for Prescription Drugs?
Patient advocates and health-care experts say the government can get into the generic pharmaceuticals business—and it wouldn’t even require a new law.
Joel Dodge and Sean McElwee